Eradication of Helicobacter pylori in Hemodialysis Patients

Figures & data

Figure 1. Demographic schema of study design. Seventy-seven hemodialysis patients underwent upper gastrointestinal endoscopy. The presence of Helicobacter pylori (H. pylori) was assessed by histology, rapid urease test and cultivation. Positive H. pylori status was assigned based upon at least two positive results. Patients who were diagnosed as being H. pylori-positive and wished to receive therapy were enrolled into this study. Patients were randomly assigned into two groups.

Figure 2. Eradication therapy.

Figure 3. Percentage of Helicobacter pylori-positive patients relative to age. Cases of Helicobacter pylori infection were not observed until age forty years or above.

Figure 4. Percentage of patients infected with Helicobacter pylori relative to the number of elapsed years since beginning dialysis. There was no correlation between the duration of patients’ hemodialysis and the prevalence of H. pylori infection. In patients with prolonged duration of hemodialysis, the proportion of H. pylori-positive patients did not change.

Figure 5. Success of treatment in eradicating Helicobacter pylori. Of the eleven patients selected to receive the LAC regimen, eradication was successful in nine (72.7%). H. pylori were eradicated in three of the nine patients (33.3%) who received the LC regimen.

Table 1 Reported frequency of H.pylori infection in haemodialysis patients in 1991∼2005

Reference	Country	Number of healthy controls	Frequency of H.pylori infection in healthy controls (%)	Number of HD patients	Frequency ofH.pylori infectionin HD patients(%)	Measuring method
Loffeld RJ (1991)[18]	Netherland	No description	No description	30	43	Serology
Jaspersen D (1995)[19]	Germany	127	37	34	20.6	UBT, histology
Luzza F (1996)[20]	Italy	103	78	103	73	Serology
Abu Farsakh NA (1996)[21]	Jordan	100	73	92	48.9	Histology
Ozgur O (1997)[22]	Turkey	100	64	47	60	UBT, histology
Munoz de Bustillo E (1998)[23]	Spain	No description	No description	52	63.5	UBT
Yildiz A (1999)[24]	Turkey	55	72.5	47	65.9	Serology
Huang JJ (2000)[25]	Taiwan	42	60	33	47.1	Culture, stain
Wang YL (2001)[26]	Taiwan	80	60	80	50	HpSA, serology
Nakajima F (2002)[27]	Japan	No description	No description	51	27.5	UBT, culture, histology
Tsukada K (2002)[12]	Japan	55	56	47	30	UBT, histology
Nakajima F (2004)[28]	Japan	138	53.3	138	36.9	Serology
Itatsu T (unpublished data)	Japan	No description	No description	77	40.3	UBT, culture, histology

Table 2 Reported percentages of cured H.pylori-infected haemodialysis patients treated from 1991–2005

Reference	Regimen	Medicine dosage (mg)	Duration of medicine (days)	Percentage cured (%)
Munoz de Bustillo E (1998)[23]	1: Omeprazole	40	14	60.8 (14/23)
	amoxycillin	1500
	2 : omeprazole	40	14	82.6 (19/23)
	clarithromycin	1000
Wang YL (2001)[26]	Omeprazole	40	7
	amoxycillin	2000
	clarithromycin	1000
Tsukada K (2002)[12]	Omeprazole	60	7	91 (10/11)
	amoxycillin	1500
	clarithromycin	800
Itatsu T (unpublished data)	1: Lansoprazole	60	7	72.7 (9/11)
	amoxycillin	750
	clarithromycin	800
	2 : Lansoprazole	60		33.3 (3/9)
	clarithromycin	400

*Regimen 2 was performed subsequent to Regimen 1.

Loffeld RJ, Peltenburg HG, Stobberingh E, vd Oever H. Prevalence of Helicobacter pylori antibodies in patients on chronic intermittent hemodialysis. Nephron 1991; 59: 250–253

 PubMedGoogle Scholar

Jaspersen D, Fassbinder W, Heinkele P, et al. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol 1995; 30: 585–588

 PubMed Web of Science ®Google Scholar

Luzza F, Imeneo M, Maletta M, et al. Helicobacter pylori-specific IgG in chronic hemodialysis patients: relationship of hypergastrinemia to positive serology. Nephrol Dial Transplant 1996; 11: 120–124

 PubMedGoogle Scholar

Abu Farsakh NA, Roweily E, Rababaa M, Butchoun R. Brief report: evaluation of the upper gastrointestinal tract in uraemic patients undergoing hemodialysis. Nephrol Dial Transplant 1996; 11: 847–850

 PubMed Web of Science ®Google Scholar

Ozgur O, Boyacioglu S, Ozdogan M, Gur G, Telatar H, Haberal M. Helicobacter pylori infection in hemodialysis patients and renal transplant recipients. Nephrol Dial Transplant 1997; 12: 289–291

 PubMed Web of Science ®Google Scholar

Munoz de Bustillo E, Sanchez Tomero JA, Sanz JC, et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron 1998; 79: 55–60

 PubMed Web of Science ®Google Scholar

Yildiz A, Besisik F, Akkaya V, et al. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Clin Transplant 1999; 13: 13–16

 PubMedGoogle Scholar

Huang JJ, Huang CJ, Ruaan MK, Chen KW, Yen TS, Sheu BS. Diagnostic efficacy of (13)C-urea breath test for Helicobacter pylori infection in hemodialysis patients. Am J Kidney Dis 2000; 36: 124–129

 PubMedGoogle Scholar

Wang YL, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. Am J Kidney Dis 2001; 38: 98–103

 PubMedGoogle Scholar

Nakajima F, Sakaguchi M, Amemoto K, et al. Helicobacter pylori in patients receiving long-term dialysis. Am J Nephrol 2002; 22: 468–472

 PubMedGoogle Scholar

Tsukada K, Miyazaki T, Katoh H, et al. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in hemodialysis patients. Scand J Gastroenterol 2002; 37: 1265–1268

 PubMed Web of Science ®Google Scholar

Nakajima F, Sakaguchi M, Oka H, et al. Prevalence of Helicobacter pylori antibodies in long-term dialysis patients. Nephrology (Carlton) 2004; 9: 73–76

 PubMedGoogle Scholar